Surrozen (SRZN) Other Working Capital Changes (2020 - 2026)
Surrozen (SRZN) posted quarterly Other Working Capital Changes of $139000.0 for Q1 2026, up 917.65% year-over-year from $13659.0 in Q1 2025, and up 131.38% quarter-over-quarter from -$443000.0 in Q4 2025.
Surrozen (SRZN) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Surrozen's Other Working Capital Changes history runs 7 years deep, the most recent figure standing at $139000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 917.65% year-over-year to $139000.0; the TTM figure through Mar 2026 stood at -$1.7 million (down 431.49% YoY), while the FY2025 annual figure was -$1.8 million, down 2477.46% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at $139000.0, up from -$443000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $2.2 million in Q3 2022, with the low at -$1.1 million in Q2 2023.
- The 5-year median for Other Working Capital Changes is -$274000.0 (2022), against an average of -$116235.3.
- The sharpest annual moves came in 2024 and 2026: Other Working Capital Changes plunged 29750.0% in 2024, then jumped 917.65% in 2026.
- Surrozen's Other Working Capital Changes stood at -$2.6 million in 2022, then jumped by 161.07% to $1.6 million in 2023, then sank by 101.27% to -$20000.0 in 2024, then plunged by 2115.0% to -$443000.0 in 2025, then jumped by 131.38% to $139000.0 in 2026.
- Business Quant data shows SRZN's Other Working Capital Changes at $139000.0 in Q1 2026, -$443000.0 in Q4 2025, and -$1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -462,000.00 |
| Jun 30, 2026 | -462,000.00 |
| Jun 30, 2026 | -462,000.00 |
| Mar 31, 2026 | 139,000.00 |
| Mar 31, 2026 | 139,000.00 |
| Mar 31, 2026 | 139,000.00 |
| Dec 31, 2025 | -443,000.00 |
| Dec 31, 2025 | -443,000.00 |
| Dec 31, 2025 | -443,000.00 |
| Sep 30, 2025 | -1.35 Mn |
| Sep 30, 2025 | -1.35 Mn |
| Sep 30, 2025 | -1.35 Mn |
| Jun 30, 2025 | -19,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | -17,000.00 |
| Mar 31, 2025 | -17,000.00 |
| Mar 31, 2025 | -17,000.00 |
| Dec 31, 2024 | -20,000.00 |
| Dec 31, 2024 | -20,000.00 |